Search clinical trials for: PF-04494700

Total 1296 results

Pfizer

Completed

PF-06741086 Long-term Treatment in Severe Hemophilia

Hemophilia A or B

Poland, Switzerland, South Africa, United States, Croatia, Brazil, Chile
Pfizer

Terminated

An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States, Canada, United Kingdom, Japan, Italy
Pfizer

Terminated

PF-06671008 Dose Escalation Study in Advanced Solid Tumors

Neoplasms

United States
Pfizer

Terminated

First in Patient Study for PF-06840003 in Malignant Gliomas

Astrocytoma | Malignant Glioma | Oligodendroglioma

United States
Pfizer

Terminated

A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations

Triple Negative Breast Neoplasms

Spain, United Kingdom, United States, Italy, Hungary, Poland
Pfizer

Completed

Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus (BUTTERFLY)

Lupus Erythematosus, Systemic

United States, Germany, Taiwan, Hungary, Poland, Colombia, Argentina, Romania, Chile, Puerto Rico, Korea, Republic of, Moldova, Republic of, Peru
Pfizer

Completed

Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects

Healthy

United States
Pfizer

Withdrawn

A Comparison Of The Pharmacokinetics Of PF-04191834 Following Single Dose Administration Of A Dispersion Formulation And A Suspension Formulation In Healthy Volunteers

Healthy
University Health Network, Toronto
Pfizer

Completed

A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

Canada
Pfizer

Completed

A Healthy Volunteer Study To Assess Relative Bioavailability Of Powder-In-Capsule And A Tablet Formulation And The Effect Of Food On The Pharmacokinetics Of The Tablet Formulation

Healthy

United States
Pfizer

Completed

A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee

Pain

Belgium
Pfizer

Completed

A Study Comparing PF-05089771 TS Capsule To PF-05089771 TS Oral Dispersion In The Fasted State

Pain

Belgium
Pfizer

Completed

Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors

Solid Tumors

United States, Belgium
Pfizer

Terminated

A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804

Non-Small Cell Lung Cancer (NSCLC)

United States
Pfizer

Completed

A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999

Healthy

United States
Pfizer

Completed

A Study Comparing PF-05089771 TS Tablet to PF-05089771 TS Oral Dispersion In The Fasted State And To PF-05089771 TS Tablet In The Fasted And Fed State

Pain

Belgium
Pfizer

Completed

A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects

Healthy

Singapore
Pfizer

Completed

Study In Healthy Adult Volunteers To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429

Healthy

Belgium
Pfizer

Completed

The Safety and Tolerability of PF-05089771 Will be Investigated in Healthy Subjects Over a 14 Day Dosing Period.

Pain

Belgium
Pfizer

Completed

A Study To Evaluate The Safety, Tolerability And Plasma Drug Levels Following A Single Dose Of PF-04995274 In Healthy Adult Volunteers

Healthy

Belgium
Pfizer
Bristol-Myers Squibb

Completed

A Single Dose Study Of PF-04620110 In Healthy Subjects

Healthy

Singapore
Pfizer

Completed

A Study To Observe The Performance Of A Tablet Form Of PF-04531083 As Evidenced By The Concentration Of PF-04531083 In The Blood With Time Following Oral Administration To Healthy Volunteers.

Chronic Pain

Belgium
Pfizer

Completed

A Study To Investigate The Clearance Of PF-04776548 From The Body Following A Very Low (Micro) Dose Of The Compound Using A Low Level Of Radiotracer To Help Quantify Expected Low Concentrations Of PF-04776548 In The Body

Human Immunodeficiency Virus (HIV)

United Kingdom
Pfizer

Completed

A Phase 1 Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03526299 In Healthy Adult Volunteers

Healthy

Singapore
Pfizer

Completed

A Study To Evaluate Whether Food Affects The Plasma Drug Levels Of A 35 mg Single Dose Of PF-04447943 Taken Orally In Healthy Adult Participants

Healthy

United States
Pfizer

Completed

A Study to Evaluate Safety, Tolerability, Plasma Drug Levels, and Cognitive Response Following Multiple Doses of a Drug in Healthy Elderly Participants.

Healthy | Elderly

United States
Pfizer

Completed

A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04629991 in Healthy Volunteers

Healthy Volunteers

Belgium
Pfizer

Terminated

To Evaluate Safety, Tolerability, Plasma Drug Levels And Other Biological Effects In Healthy Volunteers

Healthy

United States
Pfizer

Completed

Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease

Crohn's Disease

United States, Spain, Lebanon, Australia, Russian Federation, Korea, Republic of, Tunisia, Italy, Poland, Belgium, Austria, Germany, Saudi Arabia, Czechia, Hungary, Switzerland, Turkey, Slovakia, Ukraine, Georgia, Bosnia and Herzegovina and more
Pfizer

Completed

First In Human Study Of Increasing Oral Doses Of PF-04634817

Healthy

United States
Pfizer

Completed

A Study To Asses Mass Balance And Absolute Bioavailability Of 14C PF-06826647 In Healthy Male Participants

Healthy

Netherlands
Shire

Completed

Long-Term Safety Of PF-00547659 In Ulcerative Colitis (TURANDOT II)

Ulcerative Colitis

Korea, Republic of, United States, Spain, Australia, Canada, Israel, Serbia, Netherlands, Belgium, Italy, New Zealand, Austria, Bulgaria, Czechia, France, Germany, Hungary, Poland, Russian Federation, Slovakia, South Africa
Pfizer

Completed

A Study To Evaluate The Safety, Tolerability And Plasma Drug Levels Of PF-04447943 When Administered With Donepezil To Healthy Volunteer Subjects

Healthy

Singapore
Pfizer

Completed

A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects

Hypercholesterolemia

United States
Pfizer

Completed

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Spain, Israel, Korea, Republic of, Russian Federation, Turkey, Czechia, Hungary, Italy, Poland, Bulgaria, Denmark, Germany, Serbia, Austria, Slovakia, Ukraine, Georgia, Romania
Pfizer

Not yet recruiting

A STUDY TO LEARN HOW THE STUDY MEDICINE CALLED PF-07293893 AFFECTS MUSCLE BIOMARKERS OF HEALTHY ADULTS

Healthy Participants
Thomas Lund
Pfizer

Not yet recruiting

Self-administration of Subcutaneous Elranatamab in the Patients' Homes. (ERICA)

Multiple Myeloma
Emma Guttman
Pfizer

Recruiting

Ritlecitinib for Cicatricial Alopecia

Cicatricial Alopecia

United States
Massachusetts General Hospital

Recruiting

Paresthesia Free Spinal Cord Stimulation (PF-SCS)

Chronic Pain | SCS

United States
University of Milano Bicocca
Pfizer

Recruiting

A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma (CRU3)

Anaplastic Large Cell Lymphoma, ALK-Positive

Italy
Pfizer

Recruiting

PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Small Cell Lung Cancer (SCLC) | Follicular Lymphoma (FL) | Castration Resistant Prostate Cancer (CRPC)

United States, Spain, Korea, Republic of, Poland, China, Bulgaria, Russian Federation, Japan
Pfizer

Active, not recruiting

Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States, Spain, Belgium, Korea, Republic of, Taiwan, Canada, Australia, Germany, Japan, France, Italy, United Kingdom, Russian Federation, Israel, Switzerland
Pfizer

Completed

STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT

Healthy Volunteers | Hepatic Impairment

United States
Pfizer

Completed

A Study to Learn About Study Medicine Called PF-07261271 in Healthy People

Healthy

United States
Pfizer

Completed

A Study to Learn How Different Amounts of the Study Medicine Called PF-06954522 Are Tolerated and Act in the Body in Healthy Adults

Healthy Participants

United States
Maastricht University Medical Center
Pfizer

Completed

Ketohexokinase Inhibition in Hereditary Fructose Intolerance (KHKi in HFI)

HFI

Netherlands
Pfizer

Completed

Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease

Healthy | Sickle Cell Anemia

United States
Pfizer

Completed

A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants

Healthy

United States
Yale University
National Institute on Drug Abuse (NIDA)

Completed

Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal

Cannabis Dependence

United States
Pfizer

Completed

Study of Multiple Oral Doses of PF-06835919 in Healthy Adult Japanese Participants

Healthy

Belgium

3

Subscribe